文献标题：Metformin and cancer occurrence in insulin-treated type 2 diabetic patients.
文献出处：Diabetes Care. 2011 Jan;34(1):129-31.
期刊影响因子：6.718
PMID：20980415
二甲双胍可降低癌症相关性发病率和死亡率。这项研究的目的是评估二甲双胍对一系列连续胰岛素治疗患者癌症发病率的影响。
通过抽样对1340例患者进行巢式病例对照研究，按每个研究对象的年龄，性别和体重指数从同一人群中匹配对照。
在平均75.9个月随访期间，与370名对照相比，112例患者出现癌症。使用二甲双胍和磺脲类药物的患者患癌症的比例明显低。调整共患病，甘精胰岛素，胰岛素总量后，二甲双胍（不包括磺脲类药物）可降低癌症发病率（分别为OR0.46[95％CI为0.25-0.85]， P = 0.014和0.75 [0.39-1.45 ]，P=0.40，）
研究者认为：癌症风险下降可能是胰岛素治疗患者维持二甲双胍治疗的相关原因。
医脉通推荐英文摘要
Diabetes Care. 2011 Jan;34(1):129-31.
Metformin and cancer occurrence in insulin-treated type 2 diabetic patients.
Monami M, Colombi C
OBJECTIVE Metformin is associated with reduced cancer-related morbidity and mortality. The aim of this study was to assess the effect of metformin on cancer incidence in a consecutive series of insulin-treated patients.
RESEARCH DESIGN AND METHODS A nested case-control study was performed in a cohort of 1,340 patients by sampling, for each case subject, age-, sex-, and BMI-matched control subjects from the same cohort.
RESULTS During a median follow-up of 75.9 months, 112 case patients who developed incident cancer and were compared with 370 control subjects. A significantly lower proportion of case subjects were exposed to metformin and sulfonylureas. After adjustment for comorbidity, glargine, and total insulin doses, exposure to metformin, but not to sulfonylureas, was associated with reduced incidence of cancer (odds ratio 0.46 [95% CI 0.25–0.85], P = 0.014 and 0.75 [0.39–1.45], P = 0.40, respectively).
CONCLUSIONS The reduction of cancer risk could be a further relevant reason for maintaining use of metformin in insulin-treated patients.
(本网站所有内容，凡注明来源为“医脉通”，版权均归医脉通所有，未经授权，任何媒体、网站或个人不得转载，否则将追究法律责任，授权转载时须注明“来源：医脉通”。本网注明来源为其他媒体的内容为转载，转载仅作观点分享，版权归原作者所有，如有侵犯版权，请及时联系我们。)
